The weekly litigation news digest is live. Subscribe now

Bayer Intellectual Property GmbH v. Mankind Pharma Limited - 1:25-cv-01429

Bayer Intellectual Property GmbH v. Mankind Pharma Limited (Case No. 1:25-cv-01429), filed on Nov 24, 2025 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-01429
Filing Date
Nov 24, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Bayer Intellectual Property GMBH -
Mankind Pharma Limited -
Janssen Pharmaceuticals, Inc. -

Patents Involved

There is a single patent involved in this case.

Application NumberPatent Number
-US9539218B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Nov 24, 2025Summons Issued as to Mankind Pharma Limited on 11/24/2025. (mrr) (Entered: 11/24/2025)PACER Document
Nov 24, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mrr) (Entered: 11/24/2025)PACER Document
Nov 24, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Intellectual Property GMBH filed by Bayer AG, Bayer Intellectual Property GMBH. (mrr) (Entered: 11/24/2025)PACER Document
Nov 24, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2. (mrr) (Entered: 11/24/2025)PACER Document
Nov 24, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/16/2025. Date of Expiration of Patent: U.S. Patent 9,539,218 expires February 17, 2034, with pediatric exclusivity to August 17, 2034.Thirty Month Stay Deadline: 4/16/2028. (mrr) (Entered: 11/24/2025)PACER Document
Nov 24, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) (Entered: 11/24/2025)PACER Document
Nov 24, 2025COMPLAINT filed against Mankind Pharma Limited ( Filing fee $ 405, receipt number ADEDC-4845286.) - filed by Bayer Intellectual Property GMBH, Bayer AG, Janssen Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(mrr) (Entered: 11/24/2025)PACER Document